Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KETOPROFEN · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| FDC KETOPROFEN+OMEPRAZOLE | EXPERIMENTAL | One capsule of Ketoprofen 200 mg + Omeprazole 20 mg FDC once daily Treatment duration: 4 weeks |
| Ketoprofen lysinate 12.5 mg | EXPERIMENTAL | - |
| Ketoprofen lysinate 6.25 mg | EXPERIMENTAL | - |
| Matching placebo | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | Ketoprofen 100 mg b.i.d. for 5 days |
| 2 | EXPERIMENTAL | Ketoprofen 150 mg b.i.d. for 5 days |
| Name | Type | Description |
|---|---|---|
| FDC KETOPROFEN+OMEPRAZOLE | DRUG | Ketoprofen + Omeprazole FDC once daily for 4 weeks |
| KETOPROFEN(RP19583) | DRUG | Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days |
| Placebo | DRUG | Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days |
| ketoprofen 100 mg | DRUG | 100 mg b.i.d. for 5 days |
| ketoprofen | DRUG | 150 mg b.i.d. for 5 days |
Inclusion criteria: * Adults suffering from chronic inflammatory conditions, in particular, rheumatoid polyarthritis, ankylosing spondylitis (or related syndromes, such as, Reiters syndrome, psoriatic arthritis,) with a previous history or who are at risk of developing NSAID associated benign gastr...
KETOPROFEN is a small molecule drug being developed by Sanofi (SNY) for the treatment of pain. It is currently in Phase 3 clinical development, meaning it is investigational and has not yet been approved by regulatory authorities. The drug is being studied in several clinical trials for pain-related conditions.
KETOPROFEN is used for the treatment of pain. Clinical trials have evaluated it in conditions such as post-traumatic or rheumatologic acute affections of the locomotor apparatus, sore throat, and pain in general. All completed trials focused on pain as the primary condition being studied.
KETOPROFEN is being developed by Sanofi, a pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting Phase 3 clinical trials to evaluate the drug's safety and efficacy for pain treatment.
KETOPROFEN is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. All three clinical trials for KETOPROFEN are Phase 3 studies, and they have all been completed.
KETOPROFEN has been studied in three completed Phase 3 clinical trials: NCT00810121, NCT00929877, and NCT00971581. These trials enrolled a total of 1,262 participants and evaluated the drug for pain, including post-traumatic or rheumatologic conditions, sore throat, and a fixed-dose combination with omeprazole.
KETOPROFEN is the active ingredient in the product Bi-Profenid, which was studied in a clinical trial comparing Bi-Profenid 200mg to Bi-Profenid 300mg. The trial NCT00810121 evaluated these formulations for pain in patients with post-traumatic or rheumatologic acute affections of the locomotor apparatus.